Comparative Studies of the Efficacy of Combinations of SSRI Antidepressants and Antipsychotics in the Treatment of Recurrent Depressive Disorder

Dyakonov, A.L.; Лобанова, И. В.

doi:10.1007/s11055-014-9896-3

Cited by 2 publications

(3 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a study comparing olan- nov & Lobanova, 2014). However, the authors reported a minor increase in adverse events with the AMS augmented group (D'yakonov & Lobanova, 2014). These results are in line with a recent report of AMS as an effective and rapid augmentation agent for the treatment of depression, although the efficacy rate might vary between patients (Rittmannsberger, 2019).…”

Section: Discussionsupporting

confidence: 86%

“…Hence, treatment efficacy might be comparable. In a study comparing olanzapine and AMS as augmentation of SSRIs (fluoxetine and sertraline, respectively) for individuals with recurrent depressive disorder, both groups showed a significant reduction of depressive symptoms since Day 10 of the treatment till the end of the study (Day 40) (D'yakonov & Lobanova, 2014 ). However, the authors reported a minor increase in adverse events with the AMS augmented group (D'yakonov & Lobanova, 2014 ).…”

Section: Discussionmentioning

confidence: 99%

“…In a study comparing olanzapine and AMS as augmentation of SSRIs (fluoxetine and sertraline, respectively) for individuals with recurrent depressive disorder, both groups showed a significant reduction of depressive symptoms since Day 10 of the treatment till the end of the study (Day 40) (D'yakonov & Lobanova, 2014 ). However, the authors reported a minor increase in adverse events with the AMS augmented group (D'yakonov & Lobanova, 2014 ). These results are in line with a recent report of AMS as an effective and rapid augmentation agent for the treatment of depression, although the efficacy rate might vary between patients (Rittmannsberger, 2019 ).…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Efficacy of amisulpride for depressive symptoms in individuals with mental disorders: A systematic review and meta‐analysis

Zangani

Giordano

Stein

et al. 2021

Human Psychopharmacology

View full text Add to dashboard Cite

Background: Depressive symptoms occur in several psychiatric disorders, often in the absence of a formal diagnosis of depression. We aimed to evaluate the efficacy and the tolerability of amisulpride, both alone and as augmentation therapy, in the treatment of depressive symptoms in individuals with any major psychiatric disorder. Methods:We searched PubMed, Embase, PsycINFO, GreyLit, OpenGrey and Pro-Quest up to March 2020 for randomised controlled trials focussing on the treatment of an acute depressive episode in any major psychiatric disorder. A randomeffect meta-analysis was performed to synthesize the findings on depressive symptoms (primary outcome), response rate and tolerability. Results:We retrieved 11 studies including 2065 patients with a diagnosis of dysthymia (eight studies), major depression (one study) or schizophrenia (two studies). Amisulpride 50 mg/day was associated with a larger reduction of depressive symptoms compared to placebo (standardised mean difference [SMD] = −0.70, CI 95% −0.92, −0.49; I 2 = 0.0%), and was found to be comparable to selective serotonin reuptake inhibitors (SSRIs; SMD = −0.08, CI 95% −0.23, 0.06, I 2 = 0.0%), amineptine, imipramine and amitriptyline in the treatment of dysthymia (three studies, not pooled). In individuals with schizophrenia, amisulpride administered at higher doses (>400 mg/day) was comparable to olanzapine and risperidone (two studies, not pooled). In terms of tolerability, amisulpride was superior to placebo for dysthymia (odds ratio [OR] = 3.94, CI 95% 1.07, 14.48; I 2 = 0.0) and comparable with SSRIs (OR = 0.94, CI 95% 0.55, 1.62; I 2 = 0.0%). Conclusion:Treatment with amisulpride could be a valid choice for selected individuals with dysthymia or depressive symptoms in the context of schizophrenia.More studies on the efficacy and tolerability of amisulpride are needed to draw firm conclusions on its potential benefits in other psychiatric disorders.This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

show abstract

Section: Discussionsupporting

confidence: 86%

Section: Discussionmentioning

confidence: 99%